Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cardiol Therapeutics Inc. - Class A Common Shares (NQ:CRDL)

1.395 +0.175 (+14.34%)
Streaming Delayed Price Updated: 3:03 PM EDT, Jul 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cardiol Therapeutics Inc. - Class A Common Shares

< Previous 1 2 3 Next >
This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by... 
Via Newsfile
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Appoints Terry Lynch to Board, Grants Options
Via Investor Brand Network
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart
Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a... 
Via Newsfile
Why Cardiol Therapeutics (CRDL) Stock Is Down 20% Today
Cardiol Therapeutics shares are trading lower by 20% Wednesday morning. The company announced a $13.5 million public offering. 
Via Benzinga
“Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances”
Via AB Newswire
3 Penny Stocks Ready to Break Out in 2025
Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products. 
Via MarketBeat
Thanksgiving Week Oversold Stocks to Watch: CRDL, QBTS, PRSO, RGTI & More!
Via AB Newswire
“Game-Changers to Watch CRDL, RMSG, WORX, PET and more…Innovative Companies inside”
Via AB Newswire
Topics Economy
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for CardiolRx™ at the American Heart Association…more stocks inside…
Via AB Newswire
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
Via Benzinga
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!
Via AB Newswire
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially... 
Via Newsfile
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
Via AB Newswire
Topics Electric Vehicles
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN
Via AB Newswire
“Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge”
Via AB Newswire
Topics Government
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”
Via AB Newswire
Topics Artificial Intelligence
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX
Via AB Newswire
Topics Intellectual Property
Cardiol Therapeutics’ (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…
Via AB Newswire
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday
Via Benzinga
“Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…”
Via AB Newswire
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024
CRDL stock results show that Cardiol Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
In a phenomenal year marked by over +180% gains in its stock price, Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) added another feather to its cap last week with the announcement of its Phase II... 
Via TheNewswire.com
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients 
Via News Direct
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce... 
Via Newsfile
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Sector Spotlight: Orphan Drug Developers With Significant Upside
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record... 
Via TheNewswire.com
Topics ETFs
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL)
Via AB Newswire
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics
Analysts’ Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics 
Via News Direct
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
CRDL stock results show that Cardiol Therapeutics met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS